Charles Schwab Investment Management Inc. Buys 8,397 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Charles Schwab Investment Management Inc. increased its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 3.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 222,135 shares of the company’s stock after purchasing an additional 8,397 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.61% of iTeos Therapeutics worth $2,268,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the stock. The Manufacturers Life Insurance Company grew its stake in shares of iTeos Therapeutics by 6.6% during the second quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock valued at $164,000 after purchasing an additional 690 shares during the last quarter. Creative Planning boosted its stake in iTeos Therapeutics by 6.5% in the third quarter. Creative Planning now owns 19,636 shares of the company’s stock valued at $200,000 after acquiring an additional 1,196 shares during the last quarter. nVerses Capital LLC boosted its stake in iTeos Therapeutics by 212.5% in the third quarter. nVerses Capital LLC now owns 2,500 shares of the company’s stock valued at $26,000 after acquiring an additional 1,700 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in iTeos Therapeutics by 60.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,024 shares of the company’s stock valued at $72,000 after acquiring an additional 2,646 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in iTeos Therapeutics by 35.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,998 shares of the company’s stock valued at $178,000 after acquiring an additional 3,172 shares during the last quarter. 97.16% of the stock is owned by institutional investors.

Insider Buying and Selling at iTeos Therapeutics

In other iTeos Therapeutics news, CFO Matthew Gall purchased 5,000 shares of the stock in a transaction on Tuesday, November 19th. The shares were purchased at an average cost of $7.73 per share, for a total transaction of $38,650.00. Following the purchase, the chief financial officer now owns 65,429 shares of the company’s stock, valued at approximately $505,766.17. This represents a 8.27 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 12.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Wedbush reaffirmed an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of iTeos Therapeutics in a research note on Friday.

iTeos Therapeutics Stock Down 3.4 %

Shares of NASDAQ:ITOS opened at $7.68 on Monday. iTeos Therapeutics, Inc. has a 12 month low of $7.44 and a 12 month high of $18.75. The company’s fifty day simple moving average is $8.74 and its 200 day simple moving average is $12.92. The firm has a market cap of $280.58 million, a price-to-earnings ratio of -2.44 and a beta of 1.37.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. Research analysts expect that iTeos Therapeutics, Inc. will post -3.46 earnings per share for the current fiscal year.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.